Abstract Number: L07 • ACR Convergence 2024
The Classification Criteria for Anti-Synthetase Syndrome (Class) Project
Background/Purpose: The aim of this study was to develop and validate new classification criteria for Anti-Synthetase Syndrome (ASSD) using data and consensus driven methodologies and…Abstract Number: 0288 • ACR Convergence 2024
Hypersensitivity Pneumonitis with Autoimmune Features: A New Entity?
Background/Purpose: Hypersensitivity pneumonitis (HP) is an interstitial lung disease induced by inhaled antigens that trigger an interstitial and bronchoalveolar lymphocytic inflammatory response. This immune response…Abstract Number: 1112 • ACR Convergence 2024
Pleuroparenchymal Fibroelastosis Associated with Connective Tissue Diseases (PPFE-CTD)
Background/Purpose: Pleuroparenchymal Fibroelastosis (PPFE) is a rare idiopathic interstitial pneumonia characterized by fibrosis of the visceral pleura and subpleural parenchyma, predominantly affecting the upper lobes.…Abstract Number: 2058 • ACR Convergence 2024
Association of Anti-Synthetase Antibody Subtypes with Radiographic Progression of Interstitial Lung Disease in Anti-Synthetase Syndrome: An Analysis of the CLASS Project Database
Background/Purpose: In anti-synthetase syndrome (ASSD), clinical presentations vary from isolated interstitial lung disease (ILD) to systemic multi-organ manifestations. Several studies emphasize the crucial role of…Abstract Number: 0299 • ACR Convergence 2024
Real-World Tolerability of Nintedanib in Connective Tissue Disease-Associated Interstitial Lung Disease
Background/Purpose: Nintedanib is an antifibrotic medication used to treat interstitial lung disease (ILD), including connective tissue disease-associated ILD (CTD-ILD). Clinical trials that led to its…Abstract Number: 1114 • ACR Convergence 2024
Nintedanib in Autoimmune Disease-related Interstitial Lung Disease: Real-life Effectiveness, Safety and Tolerance in a Spanish Multicenter Study
Background/Purpose: Interstitial lung disease (ILD) is a severe complication of autoimmune diseases (AD). In recent years, new strategies for the treatment of progressive pulmonary fibrosis…Abstract Number: 2059 • ACR Convergence 2024
The Rs35705950 Promoter Variant of Muc5b Is Associated with Usual Interstitial Pneumonia in Antisynthetase Syndrome
Background/Purpose: Rs35705950 variant in the MUC5B gene promoter is a critical genetic risk factor in idiopathic pulmonary fibrosis (IPF). It has been associated with usual…Abstract Number: 0308 • ACR Convergence 2024
Interstitial Lung Disease as the First Clinical Manifestation of Connective Tissue Diseases
Background/Purpose: Interstitial lung disease (ILD) is a common complication of connective tissue diseases (CTDs), significantly influencing prognosis and mortality. The prevalence and characteristics of new…Abstract Number: 1169 • ACR Convergence 2024
Efficacy of Intravenous Immunoglobulin (Octagam 10%) on Pulmonary Manifestations in Patients with Dermatomyositis: Results from the ProDERM Study
Background/Purpose: Interstitial lung disease (ILD) and other pulmonary manifestations are a major cause of mortality and morbidity in patients with dermatomyositis (DM). The ProDERM study…Abstract Number: 2208 • ACR Convergence 2024
Clinical, Imaging and Treatment Characteristics of Patients with Progressive Systemic Autoimmune Rheumatic Disease-related Interstitial Lung Diseases (SARD-ILDs) in the ILD-PRO Registry
Background/Purpose: The ILD-PRO Registry is a multicenter US registry of patients with progressive fibrosing interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF). We…Abstract Number: 0317 • ACR Convergence 2024
Progressive Fibrosing Intersticial Lung Disease of Autoimmune Origin and Antifibrotic Medication: NEREA Registry
Background/Purpose: Nintedanib and pirfenidone are approved therapies for the management of patients with progressive fibrosing interstitial lung diseases (ILD), including those of autoimmune origin (ILD…Abstract Number: 1425 • ACR Convergence 2024
Sjögren’s Syndrome and Interstitial Lung Disease: Experience in a Collaborative Rheumatology-Pulmonology Clinic
Background/Purpose: Pulmonary lung disease represents the most prevalent extra-glandular manifestation in patients with Sjögren’s syndrome (SS). Notably, interstitial lung disease (ILD) stands out as the…Abstract Number: 2310 • ACR Convergence 2024
Prospective Evaluation of Pulmonary Involvement in Patients with Primary Sjögren’s Disease, Using Pulmonary Function Tests and High Resolution Computed Tomography, Reveals High Prevalence of Subclinical Interstitial Lung Disease, Along with Small Airways Disease
Background/Purpose: Interstitial lung disease (ILD) and small airways disease (SAD) are frequent pulmonary manifestations of primary Sjögren’s disease (SjD). The relation between these two entities…Abstract Number: 0331 • ACR Convergence 2024
Cardiac Manifestations in Patients with Anti-Synthetase Syndrome: Analysis from the “Classification Criteria for Anti-synthetase Syndrome (CLASS)” Project Database
Background/Purpose: The prevalence of cardiac manifestations has not been comprehensively described in anti-synthetase syndrome (ASSD). In the current study, we report the prevalence of cardiac…Abstract Number: 1501 • ACR Convergence 2024
Retrospective Cohort Study Identifying Pulmonary Complications in a Cohort of Patients with Systemic Lupus Erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with multi organ involvement. One of the most common manifestations is pulmonary disease with a…
- 1
- 2
- 3
- …
- 12
- Next Page »